Clinical trials: Chronic Obstructive Pulmonary Disease, Unspecified
- Condition Chronic Obstructive Pulmonary Disease, Unspecified
- Funder type Industry (pharma, biotech, devices)
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)
The purpose of this study is to assess the efficacy (effectiveness) and safety of aclidinium bromide doses as compared to placebo in the treatment of moderate to severe chronic obstructive pulmonary disease.
- Trial name
- NCT00891462
- Testing
- Aclidinium bromide
- Where
- 112 sites in United States, Canada
- Volunteers
- 561 people
- Sponsor
- AstraZeneca
COPD
A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world.
- Trial name
- NCT01794780
- Testing
- LABA based treatment: indacaterol, LAMA based treatment: tiotropium, LABA/ICS based treatment: salmeterol/fluticasone
- Where
- 2 sites in China
- Volunteers
- 2,229 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
General Practice Quality Assurance Project. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment
A Cross sectional observational Quality Assurance Project in General Practice to COPD Diagnosis and Treatment
- Trial name
- NCT00319813
- Testing
- Education
- Volunteers
- 8,000 people
- Sponsor
- Boehringer Ingelheim
Asthma
Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications
Glucocorticoids are important in the treatment of many inflammatory, allergic, immunologic, and malignant disorders. However, the adverse effects of systemic corticosteroids are one of the most common causes of iatrogenic…
- Trial name
- NCT06488703
- Where
- Germany
- Volunteers
- 107,032 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118
The purpose of this study is to establish single and multiple dose safety in healthy subjects and subjects with mild chronic pulmonary obstructive disease (COPD).
- Trial name
- NCT01333904
- Testing
- PUR118
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Pulmatrix Inc.
Pulmonary Disease, Chronic Obstructive
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
The primary objective of this trial is to investigate the effect of 6 weeks treatment with tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and exercise tolerance in patients with COPD.
- Trial name
- NCT01533935
- Testing
- Tiotropium + Olodaterol, Tiotropium, Olodaterol
- Where
- 33 sites in United States, Argentina and 6 more
- Volunteers
- 291 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant
The study will assess the Pharmacokinetic (PK) and safety of BGF MDI [Budesonide/glycopyrronium/formoterol (BGF) metered dose inhaler (MDI)] formulated with 2 different propellants :Hydrofluoroolefin (HFO) and Hydrofluoroalkane…
- Trial name
- NCT05477108
- Testing
- Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal)
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Respiratory (Chronic Obstructive Pulmonary Disease)
Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics
Chronic Obstructive Pulmonary Disease (COPD) is a global health concern, associated with structural lung abnormalities causing persistent airflow limitation (AL) and often result from cigarette smoking.
- Trial name
- ALSAC (NCT07315958)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Vagus Nerve Stimulation for Management of Bronchoconstriction in Patients Hospitalized With COPD Exacerbations
This study will look at the safety, improving symptoms and decreasing the length of stay of patients admitted to the hospital with COPD.
- Trial name
- NCT01612793
- Testing
- AlphaCore Device
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- ElectroCore INC
Pulmonary Disease, Chronic Obstructive
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)
This is a pilot study to investigate the effect of danirixin hydrobromide 35 milligram (mg) tablets on lung function and health related quality of life (HRQoL) in subjects with mild to moderate airflow obstruction and a…
- Trial name
- NCT03170232
- Testing
- Danirixin 35 mg tablets, Metered dose inhaler (MDI) sensor device, Rescue medication
- Where
- 11 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
The COPD Patient Management European Trial (COMET)
The goal of the study is to evaluate a Home-Based Disease Management program specifically developed for patients with Gold III/IV COPD.
- Trial name
- COMET (NCT01241526)
- Testing
- Disease Management, Usual site management
- Where
- 34 sites in France, Germany and 2 more
- Volunteers
- 346 people
- Sponsor
- Air Liquide Santé International
Pulmonary Disease, Chronic Obstructive
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered…
- Trial name
- NCT00400153
- Testing
- Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg)
- Where
- 180 sites in United States, Argentina and 11 more
- Volunteers
- 1,480 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, COPD
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations.
- Trial name
- ROMEO (NCT07566195)
- Testing
- Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2
- Where
- 13 sites in France
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Copd
Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD
The overall objective is to asses the bronchodilator effect of single dose of Formoterol/Budesonide 12/400 mcg fixed combination delivered via Discair® in patients with COPD.
- Trial name
- COPD (NCT03028701)
- Testing
- Formoterol/Budesonide 12/400 mcg Discair
- Where
- Turkey (Türkiye)
- Volunteers
- 33 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Chronic Obstructive Pulmonary Disease
Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study was designed to obtain data about the efficacy and safety of 3 doses of indacaterol (150, 300, and 600 µg) in Japanese patients with chronic obstructive pulmonary disease (COPD) so that optimal dose(s) could be chosen…
- Trial name
- NCT00403845
- Testing
- Indacaterol 150 μg, Indacaterol 300 μg
- Where
- 8 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Preference Tiotropium Respimat Study in COPD
In COPD the patient's ability to use inhalers correctly and their preference for the inhaler are both important factors in selecting an appropriate treatment for COPD.
- Trial name
- NCT01810692
- Testing
- Group1:Spiriva® Respimat®, Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®
- Where
- 15 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care
This is a prospective, observational, non-drug interventional, non-randomized study to compare the rate of moderate-severe COPD exacerbations in patients of all Chronic Obstructive Pulmonary Disease (COPD) severities with and…
- Trial name
- ACCESS (NCT01516528)
- Testing
- Spirometry
- Where
- 233 sites in Belgium, France and 4 more
- Volunteers
- 3,500 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak…
- Trial name
- NCT03095456
- Testing
- Revefenacin, Spiriva Handihaler®
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Mylan Inc.
Pulmonary Disease, Chronic Obstructive
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when…
- Trial name
- RENEW-COPD (NCT07759245)
- Testing
- Brenipatide, Standard of Care
- Where
- 127 sites in United States, Argentina and 16 more
- Volunteers
- 606 people
- Sponsor
- Eli Lilly and Company
Chronic Obstructive Pulmonary Disease
Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation
This real-world retrospective study will use de-identified administrative claims data and will examine patients with a diagnosis of COPD who have experienced a qualifying severe disease exacerbation and received subsequent…
- Trial name
- NCT07414134
- Testing
- BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
- Where
- United States
- Volunteers
- 3,598 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.